Literature DB >> 16053030

The spectrum of biopsy sites for the diagnosis of sarcoidosis.

Alvin S Teirstein1, Marc A Judson, Robert P Baughman, Milton D Rossman, Henry Yeager, David R Moller.   

Abstract

BACKGROUND: The diagnosis of sarcoidosis is most secure when supported by a tissue biopsy exhibiting noncaseating epithelioid granulomas with absence of known granulomagenic agents in a patient with multi-organ disease. Clinicians must decide which site offers the best chance of achieving a diagnostic biopsy with the least patient risk and discomfort.
METHODS: 736 cases were enrolled in the NHLBI supported A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) from November 1996 to June 1999. All cases required diagnostic organ biopsy (Bx) exhibiting non-caseating epithelioid granulomas without identifiable granulomagenic agent, within six months of recruitment. Positive Kveim-Siltzbach test was accepted in patients with Löfgren's syndrome. Bx sites were correlated with demographic data, chest radiographic stages, symptoms, pulmonary function and associated organ involvement.
RESULTS: Seven hundred and seventy-six diagnostic biopsies were performed. Five hundred and sixty-seven were intrathoracic, 198 extrathoracic. Eleven Kveim tests were positive. When cutaneous sarcoidosis or an enlarged extrathoracic lymph node was present, skin or lymph node Bx was the preferred procedure. Twenty-three different organs yielded diagnostic biopsies.
CONCLUSIONS: Biopsy diagnosis in sarcoidosis is almost always easily obtained. As shown by ACCESS, sarcoidosis offers a wide spectrum of diagnostic biopsy sites. The choice for biopsy is influenced by the presenting clinical constellation of organ involvement and the ease and safety of the biopsy procedure.

Entities:  

Mesh:

Year:  2005        PMID: 16053030

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  10 in total

1.  Asymptomatic tiny subcutaneous eruptions in a patient with sarcoid neuropathy: the effectiveness of fluorine-18 fluorodeoxyglucose positron emission tomography for targeting safe biopsy sites.

Authors:  Makoto Kobayashi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

2.  Sarcoid Uveitis: A Look Beyond The Eyes.

Authors:  Daniel Lemor; David B Lazar; W Brooks Emory; Jonathan D Nussdorf
Journal:  Ochsner J       Date:  2016

3.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27

4.  Racial differences in sarcoidosis granuloma density.

Authors:  Robert R Burke; Chad H Stone; Suzanne Havstad; Benjamin A Rybicki
Journal:  Lung       Date:  2008-08-21       Impact factor: 2.584

5.  Comorbid illnesses and chest radiographic severity in African-American sarcoidosis patients.

Authors:  Gloria E Westney; Sadia Habib; Alexander Quarshie
Journal:  Lung       Date:  2007-03-24       Impact factor: 3.777

6.  Progressive renal insufficiency, hypercalcaemia, bicytopaenia and a history of breast cancer.

Authors:  Sebastian Letterer; Ulrich Lindner; Heinz-Wolfram Bernd; Florian M Vogt; Udo Helmchen; Hendrik Lehnert; Christian S Haas
Journal:  NDT Plus       Date:  2010-10-19

7.  A rare presentation of sarcoidosis with nasal bone involvement.

Authors:  Mukadder Korkmaz; Selen Uslu; Hakan Korkmaz; Yeliz Çetinkol
Journal:  Allergy Rhinol (Providence)       Date:  2016-01

Review 8.  Contemporary optimized practice in the management of pulmonary sarcoidosis.

Authors:  Shambhu Aryal; Steven D Nathan
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

Review 9.  Pediatric Sarcoidosis: A Review with Emphasis on Early Onset and High-Risk Sarcoidosis and Diagnostic Challenges.

Authors:  Brian Chiu; Jackie Chan; Sumit Das; Zainab Alshamma; Consolato Sergi
Journal:  Diagnostics (Basel)       Date:  2019-10-25

Review 10.  [Epidemiology of sarcoidosis].

Authors:  Estrella Fernández Fabrellas
Journal:  Arch Bronconeumol       Date:  2007-02       Impact factor: 4.872

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.